- Auteur(s) : Erika Viel, Elsa Curtit, Laura Mansi, Stéphane Vignot
, CHU J.-Minjoz, service d’oncologie médicale, boulevard Fleming, 25030 Besançon, France, Groupe hospitalier Pitié-Salpêtrière, service d’oncologie médicale, boulevard de l’Hôpital, 75013 Paris, France
- Mots-clés : HER1, EGFR, molecular targeted therapy, predictive factors, KRAS, cetuximab, panitumumab, gefitinib, erlotinib
- Page(s) : 181-9
- DOI : 10.1684/bdc.2011.1385
- Année de parution : 2012
EGFR may be considered as an old target, which can be inhibited both by monoclonal antibodies and tyrosine kinase inhibitors. Those molecular targeted strategies are now approved in a wild range of tumors: colorectal cancer, lung cancer, pancreatic cancer and head and neck cancer. This paper proposes to describe the development of anti-EGFR drugs, highlighting several strategies points. Predicting biomarkers have been extensively studied for these agents, sustaining the hallmarks of the development of molecular targeting drugs.